Bioxytran reports positive results from COVID-19 antiviral trial Mar 2, 2026 11:40AM
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 Mar 2, 2026 11:40AM
Bioxytran (BIXT) Secures $1.6MSPA to Extinguish Note & Fund Clinical Development Jan 22, 2025 09:02AM
Bioxytran's Medical Breakthrough in Fighting All Viruses Sep 19, 2024 09:35AM